3.連結財務諸表及び主な注記

(1)連結財政状態計算書

 

 

(単位:百万円)

 

前連結会計年度

(2024年12月31日)

当連結会計年度

(2025年12月31日)

資産

 

 

流動資産

 

 

現金及び現金同等物

886

1,387

営業債権及びその他の債権

232

374

棚卸資産

128

112

その他の流動資産

19

15

流動資産合計

1,266

1,890

非流動資産

 

 

有形固定資産

19

16

使用権資産

28

97

持分法で会計処理されている投資

1

その他の金融資産

46

141

非流動資産合計

96

254

資産合計

1,362

2,145

 

 

 

負債及び資本

 

 

負債

 

 

流動負債

 

 

営業債務及びその他の債務

121

229

リース負債

25

31

その他の流動負債

47

51

流動負債合計

193

312

非流動負債

 

 

繰延税金負債

0

5

リース負債

0

64

その他の非流動負債

10

11

非流動負債合計

12

80

負債合計

206

393

資本

 

 

資本金

2,211

836

資本剰余金

2,255

1,455

利益剰余金

3,277

521

自己株式

65

65

その他の資本の構成要素

33

47

資本合計

1,156

1,752

負債及び資本合計

1,362

2,145

 

E3304445970ソレイジア・ファーマ株式会社Solasia Pharma K.K.通期第3号参考様式 [IFRS](連結)IFRStrueCTECTE2025-01-012025-12-31FY2025-12-312024-01-012024-12-312024-12-311falsefalsefalse459702025-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702025-01-012025-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702024-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702024-01-012024-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702023-12-31jpigp_cor:NetChangeInFairValueOfEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember459702025-12-31jpigp_cor:RetainedEarningsIFRSMember459702025-12-31jpigp_cor:CapitalSurplusIFRSMember459702025-12-31jpigp_cor:ShareCapitalIFRSMember459702025-01-012025-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702025-01-012025-12-31jpigp_cor:TreasurySharesIFRSMember459702025-01-012025-12-31jpigp_cor:RetainedEarningsIFRSMember459702025-01-012025-12-31jpigp_cor:CapitalSurplusIFRSMember459702025-01-012025-12-31jpigp_cor:ShareCapitalIFRSMember459702024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702024-12-31jpigp_cor:TreasurySharesIFRSMember459702024-12-31jpigp_cor:RetainedEarningsIFRSMember459702024-12-31jpigp_cor:CapitalSurplusIFRSMember459702024-12-31jpigp_cor:ShareCapitalIFRSMember459702024-01-012024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702024-01-012024-12-31jpigp_cor:TreasurySharesIFRSMember459702024-01-012024-12-31jpigp_cor:RetainedEarningsIFRSMember459702024-01-012024-12-31jpigp_cor:CapitalSurplusIFRSMember459702024-01-012024-12-31jpigp_cor:ShareCapitalIFRSMember459702023-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702026-02-13459702025-12-31459702025-01-012025-12-31459702024-12-31459702024-01-012024-12-31459702023-12-31459702023-12-31jpigp_cor:TreasurySharesIFRSMember459702023-12-31jpigp_cor:RetainedEarningsIFRSMember459702023-12-31jpigp_cor:CapitalSurplusIFRSMember459702023-12-31jpigp_cor:ShareCapitalIFRSMember459702025-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-01-012025-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702024-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702024-01-012024-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702023-12-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember459702025-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember459702025-01-012025-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember459702024-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember459702024-01-012024-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember459702023-12-31jpigp_cor:ShareAcquisitionRightsIFRSMember459702025-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember459702025-12-31jpigp_cor:TreasurySharesIFRSMemberiso4217:JPYxbrli:sharesiso4217:JPYxbrli:pure